NASH Asset Licensing Boston Pharmaceuticals has BOS-580, a long-acting FGF21 analog for NASH, with Phase 2 data and upcoming presentations at major hepatology conferences. This asset profile and active conference cadence signal strong licensing or co-development appeal to hepatology-focused partners. BD opportunities include out-licensing or collaboration with milestone-rich terms, potentially with regional rights and shared development costs.

Hepatology Leadership The company appointed Dr. Margaret Koziel as Chief Medical Officer in 2024 and previously named an Acting CMO in 2023, underscoring a credible clinical leadership footprint in liver diseases. Their active participation in AASLD and EASL demonstrates readiness to execute complex hepatology programs. This enhances the appeal for partners seeking solid clinical execution capabilities.

Flexible Deal Size With revenue in the $50–100 million range and a lean team (51–200 employees), Boston is well-suited for milestone-driven, mid-sized partnerships rather than large mega-deals. This enables licensing BOS-580 or other assets with clear milestones and manageable upfronts, plus potential manufacturing collaboration to support external programs.

Diverse Pipeline Boston describes a portfolio across multiple therapeutic areas and is actively seeking additional programs. This openness creates BD opportunities to source external assets, perform selective transformations, and pair partner assets with Boston’s development and manufacturing capabilities to accelerate timelines.

Cambridge Advantage Located in Cambridge, MA, the company benefits from proximity to a dense biotech ecosystem, access to talent, and potential collaborations with local CROs and manufacturers. This positioning can facilitate faster deal sourcing, due diligence, and cross-border partnerships with US and EU companies targeting hepatology and metabolic assets.